NewTradingView.com – Investing and Stock News
Investing and Stock News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Editor's Pick

RFK Jr cancels $500 million in mRNA research, HHS to prioritize ‘safer’ vaccine alternatives

by August 5, 2025
written by August 5, 2025

A total of 22 mRNA vaccine development contracts totaling roughly $500 million have been canceled, the Department of Health and Human Services (HHS) announced Tuesday.

The mRNA investments were part of the government’s Biomedical Advanced Research and Development Authority (BARDA), a division of HHS that drives some of the country’s most advanced scientific research, such as the development of vaccines, drugs and other tools to fight national health threats. The termination of the 22 BARDA contracts follows a several-weeks-long internal review to determine a path forward when it comes to these investments.

‘We reviewed the science, listened to the experts, and acted,’ HHS Secretary Robert F. Kennedy Jr. said Tuesday. ‘BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.’

In a short video explaining the move, Kennedy said the benefits simply do not outweigh the risks associated with mRNA vaccines. 

Kennedy went on to point out that not only do mRNA vaccines – as shown during the COVID-19 pandemic – not perform well against viruses that infect the upper respiratory tract, but they also do not defend against mutations of the viruses they are intended to go after.

‘This dynamic drives a phenomena called anogenic shift, meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine,’ Kennedy said in the video.

For example, the HHS secretary pointed to the omicron variant of the COVID-19 virus, which infected many millions, including those who had been vaccinated against COVID. 

‘A single mutation can make mRNA vaccines ineffective,’ Kebbedy added, noting that the same risks also apply to the flu virus. 

The move to cancel the mRNA contracts under BARDA will not entirely cancel all mRNA vaccine research done by the government, a source familiar with the move indicated. In addition to allowing some final-stage contracts to run their course to completion in an effort to preserve prior taxpayer investments, ongoing mRNA research at the National Institutes of Health (NIH) will not be impacted by this latest move. 

Meanwhile, in lieu of the terminated mRNA research and investments at BARDA, HHS will focus on ‘safer, broader vaccine strategies,’ Kennedy indicated.

‘To replace the troubled mRNA programs, we’re prioritizing the development of safer, broader vaccine strategies like whole virus vaccines and novel platforms that don’t collapse when viruses mutate,’ Kennedy said in his video explanation about the terminated mRNA investments.

During the video, Kennedy reiterated his support for ‘safe, effective vaccines’ for any American who wants them.

‘That’s why we’re moving beyond the limitations of mRNA for respiratory viruses and investing in better solutions.’

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
Senate GOP ready to go nuclear after Schumer’s ‘political extortion’ of nominees
next post
Marjorie Taylor Greene urges Trump to commute George Santos’ federal prison sentence: ‘Far worse offenses’

You may also like

Legal group sues FDA over puberty blocker records,...

August 30, 2025

Lawyers for Cook, DOJ trade blows at high-stakes...

August 29, 2025

House investigators nix Mueller testimony in Epstein probe...

August 29, 2025

Is Putin stringing Trump along to sidestep US...

August 29, 2025

Witkoff meets Ukraine officials in New York ahead...

August 29, 2025

Senators demand oversight, reject vaccine guidance as illegitimate...

August 29, 2025

White House move to cancel $4.9B foreign aid...

August 29, 2025

Meet the radical anti-Israel activists joining ‘Squad’ Dem...

August 29, 2025

Abbott signs Texas redistricting map into law, securing...

August 29, 2025

2028 looks like trouble for Democrats — and...

August 29, 2025
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!




    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular Posts

    • 1

      Oil and natural gas: Oil is back on the positive side

    • 2

      The dollar index continues to pull back to a new low

    • 3

      Gold and Silver: Gold remains stable in the $2420 zone

    • 4

      IonQ Stock Review: Should You Consider Investing Now?

    • 5

      Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

    Recent Posts

    • Legal group sues FDA over puberty blocker records, citing alleged Biden-era cover-up

      August 30, 2025
    • Lawyers for Cook, DOJ trade blows at high-stakes clash over Fed firing

      August 29, 2025
    • Retail panic: What the end of the ‘de minimis’ exemption means for brands across the globe

      August 29, 2025
    • House investigators nix Mueller testimony in Epstein probe over health concerns

      August 29, 2025
    • Is Putin stringing Trump along to sidestep US sanctions while bombing Ukraine?

      August 29, 2025

    Categories

    • Economy (20)
    • Editor's Pick (317)
    • Investing (20)
    • Stock (52)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: NewTradingView.com, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 NewTradingView.com All Rights Reserved.


    Back To Top
    NewTradingView.com – Investing and Stock News
    • Investing
    • Stock
    • Economy
    • Editor’s Pick